Zacks Rating on Alkermes plc (ALKS)

Alkermes plc (ALKS) : Zacks Investment Research ranks Alkermes plc (ALKS) as 2, which is a Buy recommendation. 3 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 1 more believe that the stock has more downside risks, hence they propose a Strong Sell. The average broker rating of 4 research analysts is 1.83, which indicates as a Buy.

Alkermes plc (ALKS) : Currently there are 3 street experts covering Alkermes plc (ALKS) stock. The most bullish and bearish price target for the stock is $66 and $60 respectively for the short term. The average price target of all the analysts comes to $62.67. The estimated standard deviation from the target is $3.06.


Alkermes plc has lost 0.58% in the last five trading days and dropped 7.22% in the last 4 weeks. Alkermes plc is up 7.09% in the last 3-month period. Year-to-Date the stock performance stands at -41.42%. Alkermes plc (NASDAQ:ALKS): stock turned positive on Tuesday. Though the stock opened at $45.66, the bulls momentum made the stock top out at $46.88 level for the day. The stock recorded a low of $45.5314 and closed the trading day at $46.5, in the green by 2.54%. The total traded volume for the day was 926,555. The stock had closed at $45.35 in the previous days trading.

Alkermes Public Limited Company is a biopharmaceutical company. The Company is engaged in researching, developing and commercializing, both with partners and on its own, pharmaceutical products that are designed to meet unmet medical needs of patients in major therapeutic areas. The Company has a portfolio of more than 20 products and a clinical pipeline of product candidates being developed for the treatment of central nervous system (CNS) disorders, such as addiction, schizophrenia and depression. The Company is conducting clinical studies on new pharmaceutical products. These include Aripiprazole Lauroxil, ALKS 5461, ALKS 3831, ALKS 8700 and RDB 1419. The Companys main marketed products include RISPERDAL CONSTA, INVEGA SUSTENNA/XEPLION, AMPYRA/FAMPYRA, BYDUREON and VIVITROL.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.